These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15149645)

  • 21. Role of urokinase inhibitors in choroidal neovascularization.
    Das A; McGuire P
    Semin Ophthalmol; 2006; 21(1):23-7. PubMed ID: 16517441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A structural mechanism of flavonoids in inhibiting serine proteases.
    Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
    Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.
    Islam I; Yuan S; West CW; Adler M; Bothe U; Bryant J; Chang Z; Chu K; Emayan K; Gualtieri G; Ho E; Light D; Mallari C; Morser J; Phillips G; Schaefer C; Sukovich D; Whitlow M; Chen D; Buckman BO
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3372-3375. PubMed ID: 30201291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
    J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
    Al-Ejeh F; Croucher D; Ranson M
    Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
    Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.
    Hu Y; González-Martínez D; Kim SH; Bouloux PM
    Biochem J; 2004 Dec; 384(Pt 3):495-505. PubMed ID: 15324302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
    Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
    Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
    Sevillano N; Bohn MF; Zimanyi M; Chen Y; Petzold C; Gupta S; Ralston CY; Craik CS
    Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140562. PubMed ID: 33221341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
    Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
    J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.
    Medcalf RL; Stasinopoulos SJ
    FEBS J; 2005 Oct; 272(19):4858-67. PubMed ID: 16176260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
    Al-Sha'er MA; Khanfar MA; Taha MO
    J Mol Model; 2014 Jan; 20(1):2080. PubMed ID: 24469103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase plasminogen activator (uPA) is a positive regulator of outer root sheath keratinocyte proliferation.
    Cui ZH; Yang T; Gao QG; Wang Y
    Cell Biol Int; 2004; 28(8-9):571-5. PubMed ID: 15350591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.